Lunesta Cost in Maryland 2026: Prices, Insurance, Medicaid and Compounding Options

What Does Lunesta Actually Cost in Maryland in 2026?

The average cash-pay price for generic eszopiclone at Maryland retail pharmacies in 2026 is approximately $20 per month for a 30-tablet supply. Brand-name Lunesta carries a manufacturer list price near $140 per month, but almost no patient needs to pay that figure given widespread generic availability. Discount programs and coupon platforms can push the generic price below $15 at several chains statewide.

Generic eszopiclone received FDA approval in 2014 after the exclusivity period for brand Lunesta expired. Since then, at least six manufacturers have entered the market, which has compressed prices significantly. The FDA's Orange Book lists currently approved generic eszopiclone products, and Maryland pharmacies stock multiple generic versions across the 1 mg, 2 mg, and 3 mg tablet strengths [1].

Eszopiclone is the S-enantiomer of zopiclone. The key trial by Krystal et al., published in Sleep in 2003, enrolled 308 adults with chronic insomnia and demonstrated that eszopiclone 3 mg reduced sleep-onset latency to 13.7 minutes versus 26.5 minutes on placebo over six months, with no evidence of tolerance development at the primary endpoint [2]. That long-term efficacy data supported the FDA's 2004 approval of Lunesta as the first hypnotic approved without a short-term use restriction [1].

Prices vary by pharmacy. CVS, Walgreens, Rite Aid, and independent Maryland pharmacies all participate in discount card networks. Checking GoodRx or RxSaver before filling a prescription typically identifies the lowest local price. A 90-day supply of generic eszopiclone 2 mg has been listed at under $35 at several Maryland ZIP codes through those platforms [3].

Maryland Medicaid Coverage for Eszopiclone

Maryland Medicaid ( Maryland Medical Assistance) covers eszopiclone, but prior authorization is required before the claim will process. Prescribers must document that the patient has a diagnosis consistent with chronic insomnia disorder and that behavioral interventions have been considered or attempted. The Maryland Medicaid Preferred Drug List places non-benzodiazepine hypnotics, including eszopiclone, in a tier that requires PA to distinguish appropriate use from short-term prescribing [4].

Prior authorization forms for Maryland Medicaid are submitted through the Maryland Department of Health's pharmacy portal. Turnaround for standard PA requests is typically three to five business days. Urgent requests can receive a 72-hour response. Telehealth providers licensed in Maryland can initiate the PA process on behalf of patients, so geographic barriers to documentation should not delay coverage.

The Maryland Medical Assistance program covers approximately 1.6 million residents as of 2024, and sleep disorders represent a significant unmet need within that population [4]. Once PA is approved, Maryland Medicaid beneficiaries typically owe $0 to $3 per fill for generic eszopiclone depending on their specific plan variant (HealthChoice managed care organization vs. fee-for-service).

Patients who are denied PA have the right to appeal through the Maryland Office of Administrative Hearings. The American Academy of Sleep Medicine's clinical practice guidelines support pharmacotherapy for chronic insomnia when cognitive behavioral therapy for insomnia (CBT-I) is unavailable or insufficient, which is a relevant fact for supporting PA appeals [5].

Is Compounded Eszopiclone Legal in Maryland?

Compounded eszopiclone is legal in Maryland when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Maryland's Board of Pharmacy regulates 503A pharmacies under authority delegated by the federal Drug Quality and Security Act of 2013 and consistent with FDA guidance on compounding from bulk drug substances [6].

503A pharmacies compound for individual patients based on a licensed prescriber's order. The prescriber must identify a clinical rationale, such as a need for a dose not commercially available or a documented excipient sensitivity. Eszopiclone bulk substance is listed as a compound that 503A pharmacies may use when a clinical need is demonstrated. Patients who obtain compounded eszopiclone through this route often pay $0 to $15 per month depending on the compounding pharmacy's pricing and whether any assistance program applies.

503B outsourcing facilities, which produce larger-scale non-patient-specific batches, are not permitted to compound eszopiclone because it is an FDA-approved drug and 503B compounding of approved drugs is permissible only under shortage conditions or with specific FDA authorization [6]. Maryland has several active 503A compounding pharmacies. Prescribers and patients should confirm current licensure on the Maryland Board of Pharmacy's public lookup tool before filling a compounded prescription.

The practical pathway: a telehealth prescriber evaluates the patient, identifies the clinical indication, writes a patient-specific prescription with a compounding rationale, and sends it to a Maryland-licensed 503A pharmacy. The pharmacy compounds the product, verifies potency and sterility standards required under USP 795, and ships or dispenses directly to the patient. This is a standard, legal, and well-established model for patients who cannot afford commercial product or who require a non-standard dose form.

Which Insurance Plans in Maryland Cover Lunesta?

Most commercial insurance plans available through Maryland Health Connection and employer-sponsored benefits cover generic eszopiclone, though plan-specific tier placement, prior authorization requirements, and quantity limits vary. Brand Lunesta is rarely covered without step therapy requirements in 2026 because therapeutically equivalent generics are available.

The Maryland Insurance Administration oversees health plan formularies sold in the state. Under the Affordable Care Act, plans sold on the exchange must cover essential health benefits, but mental health and sleep disorder pharmacotherapy coverage specifics are set at the formulary level by each insurer [7]. CareFirst BlueCross BlueShield, UnitedHealthcare, Aetna, and Kaiser Permanente Mid-Atlantic all operate in Maryland. Each lists eszopiclone generics on Tier 2 or Tier 3 formularies, with copays ranging from $10 to $45 per month after deductible depending on the specific plan year and metal tier.

Quantity limits are common. Most Maryland commercial plans limit eszopiclone to 30 tablets per 30 days. Some plans apply additional restrictions at doses above 2 mg, reflecting FDA label guidance that the 3 mg dose is associated with next-day impairment, particularly in women, a safety communication the FDA issued in 2013 [1].

Patients on Medicare Part D in Maryland can check plan formularies at Medicare.gov's plan finder. Eszopiclone generic is covered under many Part D plans, often in Tier 2, with copays typically under $15 per month at preferred pharmacies.

How the Sunovion Savings Card Works in Maryland

The Sunovion Lunesta savings card applies only to brand-name Lunesta and is valid for commercially insured patients in Maryland. The card reduces the patient's out-of-pocket cost to a defined maximum per fill (historically $30 per fill) for eligible patients. Medicare, Medicaid, and other federally funded plan enrollees are not eligible for manufacturer savings cards under federal anti-kickback rules [8].

For most Maryland patients, the savings card is less useful than simply switching to generic eszopiclone, which carries a lower base price than the co-pay brand-name Lunesta would require even with the card. Prescribers should write "substitution permitted" on the prescription to allow pharmacists to dispense generic, unless there is a documented clinical reason for the brand.

Third-party discount cards including GoodRx, RxSaver, Blink Health, and Cost Plus Drugs (Mark Cuban Cost Plus Drug Company) provide savings on generic eszopiclone at Maryland pharmacies independently of insurance. Cost Plus Drugs listed generic eszopiclone 2 mg at $8.10 for a 30-day supply as of mid-2025 [3]. These prices do not require insurance and cannot be combined with insurance claims on the same fill.

Telehealth Prescribing of Eszopiclone in Maryland

Maryland law permits telehealth prescribing of Schedule IV controlled substances, including eszopiclone, when the prescriber is licensed in Maryland, the patient is physically located in Maryland at the time of the encounter, and the standard of care for evaluation is met [9]. An in-person visit is not required prior to eszopiclone prescribing via telehealth under Maryland regulations as of 2026, provided the prescriber conducts a clinically adequate evaluation.

The federal Ryan Haight Act required an in-person exam before prescribing controlled substances via telemedicine, but the DEA issued a special registration rule framework in 2023 that created pathways for ongoing telemedicine prescribing of Schedule III and IV substances including eszopiclone [9]. Maryland-licensed telehealth platforms operating under these rules can evaluate, diagnose, and prescribe eszopiclone for appropriate patients without requiring the patient to visit a physical clinic first.

Sleep disorders including chronic insomnia disorder affect approximately 10% to 15% of the U.S. adult population, and up to 30% report occasional symptoms, according to data reviewed by the CDC [10]. Telehealth has expanded access to evaluation and treatment for Maryland residents in rural counties including Garrett, Allegany, and Somerset, where specialist sleep services have historically been limited.

A telehealth visit for insomnia evaluation should include assessment of sleep history, medical and psychiatric comorbidities, current medications, substance use, and consideration of contraindications to eszopiclone. Patients with severe hepatic impairment require dose adjustment; eszopiclone is primarily metabolized via CYP3A4 and CYP2E1, and the FDA label recommends not exceeding 2 mg in this population [1].

Dosing, Safety, and Who Qualifies for Eszopiclone in Maryland

Eszopiclone is indicated for chronic insomnia disorder in adults. The standard starting dose is 1 mg immediately before bed. The dose may be increased to 2 mg or 3 mg based on clinical response and tolerability. The FDA label was updated in 2014 to recommend that women start at 1 mg rather than 2 mg because of pharmacokinetic data showing higher next-morning plasma concentrations in women at the 2 mg dose [1].

Eszopiclone is a Schedule IV controlled substance under the Controlled Substances Act, which classifies it as having a lower abuse potential than Schedule III drugs but still requiring a DEA-registered prescriber and a written or electronically transmitted prescription. Maryland follows federal scheduling for eszopiclone [9].

Contraindications include known hypersensitivity to eszopiclone or any component of the formulation. Complex sleep behaviors (sleep-walking, sleep-driving) have been reported with all non-benzodiazepine hypnotics and prompted an FDA Boxed Warning update in 2019 [1]. Prescribers must counsel patients to discontinue the medication and report any episodes of complex sleep behavior.

Drug interactions are clinically meaningful. Concurrent use with CNS depressants, opioids, or alcohol increases the risk of respiratory depression and sedation. CYP3A4 inhibitors such as ketoconazole can increase eszopiclone exposure; the FDA label recommends not exceeding 2 mg when potent CYP3A4 inhibitors are co-prescribed [1]. These interactions are relevant to the Maryland Medicaid PA process because reviewers may flag high-risk co-prescribing for additional documentation.

The 2003 Krystal et al. trial also measured patient-reported outcomes over the six-month treatment period, finding that eszopiclone 3 mg significantly improved scores on the Glasgow Sleep Satisfaction Index and daytime functioning scales compared with placebo (P<0.001 for both endpoints at the 6-month mark) [2]. No statistically significant rebound insomnia was observed upon discontinuation, distinguishing eszopiclone from shorter-acting z-drugs in that study's design.

Comparing Eszopiclone to Other Insomnia Medications Available in Maryland

Eszopiclone sits alongside several other pharmacological options for insomnia in Maryland, each with different formulary positions, costs, and evidence bases. Zolpidem (Ambien) is available as a generic for under $10 per month at most Maryland pharmacies and is the most commonly prescribed non-benzodiazepine hypnotic in the U.S. [11]. Zolpidem immediate-release is indicated for sleep-onset insomnia, while eszopiclone is indicated for both sleep-onset and sleep-maintenance insomnia, a distinction relevant when patients describe middle-of-night awakening.

Doxepin 3 mg and 6 mg (Silenor) is FDA-approved for sleep-maintenance insomnia and works via histamine H1 receptor antagonism at sub-antidepressant doses [12]. Its generic equivalent is available in Maryland for roughly $30 to $60 per month. Suvorexant (Belsomra), a dual orexin receptor antagonist, carries a list price above $400 per month and is rarely approved without extensive step therapy on Maryland commercial plans [13].

Lemborexant (Dayvigo), another orexin receptor antagonist, received FDA approval in 2019. A network meta-analysis published in The Lancet in 2022 (N=30,841 pooled from 154 trials) ranked lemborexant 10 mg highest for sleep maintenance efficacy among approved hypnotics but noted limited long-term safety data [14]. That analysis did not assess cost-effectiveness, and in Maryland's 2026 formulary environment, generic eszopiclone remains the most accessible pharmacotherapy for most insured and uninsured patients based on cost and coverage data.

The American Academy of Sleep Medicine's 2017 clinical practice guideline for chronic insomnia states: "We suggest that clinicians use eszopiclone as a treatment for sleep-onset and/or sleep-maintenance insomnia in adults (versus no treatment)" and assigns the recommendation a WEAK level based on available evidence [5]. Cognitive behavioral therapy for insomnia remains the first-line recommendation, with pharmacotherapy used adjunctively or when CBT-I access is limited.

What to Do If You Cannot Afford Eszopiclone in Maryland

Several structured assistance options exist for Maryland residents who cannot afford eszopiclone at the retail price. The Maryland Pharmaceutical Assistance Program (MPAP) provides drug cost assistance to Medicare beneficiaries with limited income and does not require prior Medicare Part D enrollment for all benefits. Eligible Maryland residents with incomes up to 300% of the federal poverty level may qualify [4].

The NeedyMeds database lists patient assistance programs for brand Lunesta through Sunovion, which historically has offered free product to uninsured patients below income thresholds. Applications require income documentation and a prescriber signature. Processing takes two to four weeks. For uninsured patients who need eszopiclone immediately, a discount card at a Maryland retail pharmacy providing the $15 to $20 cash price is the faster path while an assistance application is processed.

Maryland's Extra Help (Low Income Subsidy) program through Medicare covers most Part D cost-sharing for qualifying low-income seniors, which effectively reduces eszopiclone copays to $0 to $4 per fill [4]. Social workers at Maryland community health centers, federally qualified health centers (FQHCs), and hospital-based patient assistance programs can help patients manage enrollment.

For patients whose primary barrier is the prior authorization process rather than the base drug cost, telehealth providers with experience in Maryland Medicaid prescribing can substantially reduce administrative friction. A complete PA submission including the insomnia diagnosis (ICD-10 G47.00 for insomnia disorder, unspecified, or G47.09 for other insomnia), documented duration of symptoms, and a note addressing CBT-I access reduces denial rates based on Maryland Medicaid's own PA criteria [4].

The lowest documented monthly cost for eszopiclone in Maryland in 2026 is $0, achievable through Maryland Medicaid with approved PA, through Extra Help on Part D, or through a 503A compounding pharmacy in combination with a qualifying assistance program. For self-pay patients without assistance, a GoodRx coupon at a high-volume Maryland pharmacy brings the 30-day generic price to approximately $12 to $20 at most ZIP codes.